Condition: Pulmonary Arterial Hypertension · Sponsor: AOP Orphan Pharmaceuticals AG
TripleTRE investigates the effect of initial triple combination therapy (oral endothelin receptor antagonist (ERA) + oral phosphodiesterase tyüe-5 inhibitor (PDE-5i) + parenteral treprostinil) compared to double oral therapy (oral ERA + oral PDE-5i) in pulmonary arterial hypertension (PAH) patients (group I) with intermediate-high risk or patients with intermediate-low risk with severe hemodynamic impairment at baseline in a prospective, randomized, unblinded setting with scope of increasing evidence for optimization of therapy concepts in PAH. The effect of initial triple combination therapy vs initial double oral therapy (standard of care (SoC)) will be measured by primary endpoint: (non)response to the assigned treatment.
This description comes directly from the study's public registry record.
Clinical Project Manager · +43676 3464650 · tripletre@aoporphan.com
Always discuss trial participation with your own doctor first.
| Ordensklinikum Linz | Linz, Austria | Recruiting |
| Medical University Vienna | Vienna, Austria | Recruiting |
| Fakultní Nemocnice Olomouc | Olomouc, Czechia | Not Yet Recruiting |
| Všeobecná fakultní nemocnice v Praze | Prague, Czechia | Not Yet Recruiting |
| Hôpital Bicêtre-- Assistance Publique Hopitaux de Paris | Paris, France | Not Yet Recruiting |
| Hôpitaux Universitaires de Strasbourg | Strasbourg, France | Not Yet Recruiting |
| DRK Kliniken Berlin Westend | Berlin, Germany | Not Yet Recruiting |
| University Hospital Carl Gustav Carus of Technical University Dresden | Dresden, Germany | Not Yet Recruiting |
| Universitätsmedizin Greifswald | Greifswald, Germany | Not Yet Recruiting |
| Gottsegen National Cardiovascular lnstitute | Budapest, Hungary | Not Yet Recruiting |
| Medical University of Szeged | Szeged, Hungary | Not Yet Recruiting |
| Sapienza University of Rome | Rome, Italy | Recruiting |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06317805